Review Article Supports Interchangeability of Infliximab and CT-P13

Goodwin
Contact

Last week, an article reviewing the literature comparing infliximab biosimilar CT-P13 (Celltrion) with infliximab (Janssen Biotech) for the treatment of rheumatologic diseases was published in Drug Design, Development and Therapy. Noting that many European specialists had reported having only a basic knowledge of biosimilars, the authors sought to critically analyze the clinical outcomes observed in CT-P13 randomized clinical trials, as well as the first real-life data reported by observational studies. The authors concluded that “available data from comparative [randomized clinical trials] and observational studies strongly confirmed the equivalence between CT-P13 and infliximab RP from a pharmacodynamic and a clinical point of view.” Moreover, “findings suggested interchangeability between infliximab RP and CT-P13 as a feasible and safe strategy to be applied in real-life clinical practice.”

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Goodwin

Written by:

Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide